Liquid biopsy heralds a revolution in the management of cancer, but it is limited by the key challenge of low input levels of cell free DNA (cfDNA).
BIOCAPTIVA are developing technology, the BIOCOLLECTOR, which will be transformational for liquid biopsy testing. Providing up to 100 times more cfDNA than a venous blood draw, it will open new avenues for more comprehensive genome analysis and more precise and enhanced clinical decisions particularly for early detection of cancer thereby unlocking the potential of liquid biopsy.
Location: United Kingdom, Scotland, City of Edinburgh
Member count: 1-10
Total raised: $2.643118M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 17.07.2021 | Archangels | archangels... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 01.06.2022 | Seed | $2.643118M | - | finsmes.co... |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| 01.06.2022 | Biocaptiva... | Biocaptiva Ltd, an Edinburgh, ... | UK | - | finsmes.co... |